| Pirtobrutinib in relapsed or refractory B-cell malignancies (BRUIN): a phase 1/2 study AR Mato, NN Shah, W Jurczak, CY Cheah, JM Pagel, JA Woyach, ... The Lancet 397 (10277), 892-901, 2021 | 351 | 2021 |
| Bispecific anti-CD20, anti-CD19 CAR T cells for relapsed B cell malignancies: a phase 1 dose escalation and expansion trial NN Shah, BD Johnson, D Schneider, F Zhu, A Szabo, CA Keever-Taylor, ... Nature Medicine 26 (10), 1569-1575, 2020 | 350 | 2020 |
| Ruxolitinib for the treatment of steroid-refractory acute GVHD (REACH1): a multicenter, open-label phase 2 trial M Jagasia, MA Perales, MA Schroeder, H Ali, NN Shah, YB Chen, S Fazal, ... Blood, The Journal of the American Society of Hematology 135 (20), 1739-1749, 2020 | 223 | 2020 |
| Optimizing chimeric antigen receptor T-cell therapy for adults with acute lymphoblastic leukemia NV Frey, PA Shaw, EO Hexner, E Pequignot, S Gill, SM Luger, ... Journal of Clinical Oncology 38 (5), 415, 2020 | 199 | 2020 |
| Multi Targeted CAR-T Cell Therapies for B-cell Malignancies N Shah, T Maatman, PN Hari, B Johnson Frontiers in Oncology 9, 146, 2019 | 178 | 2019 |
| Real-world outcomes and management strategies for venetoclax-treated chronic lymphocytic leukemia patients in the United States AR Mato, M Thompson, JN Allan, DM Brander, JM Pagel, CS Ujjani, ... Haematologica 103 (9), 1511, 2018 | 164 | 2018 |
| Belumosudil for chronic graft-versus-host disease after 2 or more prior lines of therapy: the ROCKstar Study C Cutler, SJ Lee, S Arai, M Rotta, B Zoghi, A Lazaryan, A Ramakrishnan, ... Blood, The Journal of the American Society of Hematology 138 (22), 2278-2289, 2021 | 163* | 2021 |
| Closed-system manufacturing of CD19 and dual-targeted CD20/19 chimeric antigen receptor T cells using the CliniMACS Prodigy device at an academic medical center F Zhu, N Shah, H Xu, D Schneider, R Orentas, B Dropulic, P Hari, ... Cytotherapy 20 (3), 394-406, 2018 | 112 | 2018 |
| National Marrow Donor Program–sponsored multicenter, phase II trial of HLA-mismatched unrelated donor bone marrow transplantation using post-transplant cyclophosphamide BE Shaw, AM Jimenez-Jimenez, LJ Burns, BR Logan, F Khimani, ... Journal of clinical oncology 39 (18), 1971, 2021 | 107 | 2021 |
| Efficacy, toxicity, and infectious complications in ruxolitinib-treated patients with corticosteroid-refractory graft-versus-host disease after hematopoietic cell transplantation S Abedin, E McKenna, S Chhabra, M Pasquini, NN Shah, J Jerkins, ... Biology of Blood and Marrow Transplantation 25 (8), 1689-1694, 2019 | 94 | 2019 |
| R‐CHOP versus dose‐adjusted R‐EPOCH in frontline management of primary mediastinal B‐cell lymphoma: a multi‐centre analysis NN Shah, A Szabo, SF Huntington, N Epperla, N Reddy, S Ganguly, ... British journal of haematology 180 (4), 534-544, 2018 | 86 | 2018 |
| Tumor lysis, adverse events, and dose adjustments in 297 venetoclax-treated CLL patients in routine clinical practice LE Roeker, CP Fox, TA Eyre, DM Brander, JN Allan, SJ Schuster, ... Clinical Cancer Research 25 (14), 4264-4270, 2019 | 75 | 2019 |
| Autologous transplantation versus allogeneic transplantation in patients with follicular lymphoma experiencing early treatment failure SM Smith, J Godfrey, KW Ahn, A DiGilio, S Ahmed, V Agrawal, ... Cancer 124 (12), 2541-2551, 2018 | 75 | 2018 |
| Allogeneic stem cell transplantation for chronic lymphocytic leukemia in the era of novel agents LE Roeker, P Dreger, JR Brown, OB Lahoud, TA Eyre, DM Brander, ... Blood Advances 4 (16), 3977-3989, 2020 | 71 | 2020 |
| Outcomes of front‐line ibrutinib treated CLL patients excluded from landmark clinical trial AR Mato, LE Roeker, JN Allan, JM Pagel, DM Brander, BT Hill, ... American journal of hematology 93 (11), 1394-1401, 2018 | 66 | 2018 |
| Safety and Effectiveness of Vedolizumab in Patients with Steroid-Refractory Gastrointestinal Acute Graft-versus-Host Disease: A Retrospective Record Review Y Fløisand, VL Lazarevic, J Maertens, J Mattsson, NN Shah, P Zachée, ... Biology of Blood and Marrow Transplantation 25 (4), 720-727, 2019 | 63 | 2019 |
| Safety and Effectiveness of Vedolizumab in Patients with Steroid-Refractory Gastrointestinal Acute Graft-versus-Host Disease: A Retrospective Record Review Y Fløisand, VL Lazarevic, J Maertens, J Mattsson, NN Shah, P Zachée, ... Biology of Blood and Marrow Transplantation 25 (4), 720-727, 2019 | 63 | 2019 |
| Is autologous transplant in relapsed DLBCL patients achieving only a PET+ PR appropriate in the CAR T-cell era? NN Shah, KW Ahn, C Litovich, Y He, C Sauter, TS Fenske, M Hamadani Blood, The Journal of the American Society of Hematology 137 (10), 1416-1423, 2021 | 60 | 2021 |
| Tocilizumab, tacrolimus and methotrexate for the prevention of acute graft-versus-host disease: low incidence of lower gastrointestinal tract disease WR Drobyski, A Szabo, F Zhu, C Keever-Taylor, KM Hebert, R Dunn, ... Haematologica 103 (4), 717, 2018 | 57 | 2018 |
| Early positron emission tomography/computed tomography as a predictor of response after CTL019 chimeric antigen receptor–T-cell therapy in B-cell non-Hodgkin lymphomas NN Shah, SJ Nagle, DA Torigian, MD Farwell, WT Hwang, N Frey, ... Cytotherapy 20 (12), 1415-1418, 2018 | 53 | 2018 |
